Accessibility Statement Skip Navigation
  • PRNewswire.com
  • Resources
  • +91 22-69790010
  • Client Login
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please use Advanced Search to search all press releases.
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +91 22-69790010 from 9 AM - 5:30 PM IST

    • Contact
    • Contact

      +91 22-69790010
      from 9 AM - 5:30 PM IST

  • Request More Information
  • Journalists
  • Request More Information
  • Journalists
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Request More Information
  • Journalists
  • Request More Information
  • Journalists

SI Group to Acquire Antioxidants, Ibuprofen and Propofol Businesses from Albemarle
  • USA - English
  • Brazil - Português
  • Latin America - español

SI Group Corporate Logo. (PRNewsFoto/SI Group, Inc.) (PRNewsFoto/)

News provided by

SI Group, Inc.

17 Apr, 2014, 01:33 IST

Share this article

Share toX

Share this article

Share toX

SCHENECTADY, New York, April 16, 2014 /PRNewswire/ -- SI Group, Inc. announced today that it has signed a deal to acquire the Antioxidants, Ibuprofen, and related businesses and assets from Albemarle Corporation (NYSE:ALB). The transaction includes manufacturing sites in Orangeburg, South Carolina, United States and Jinshan, China.  This deal expands SI Group's antioxidants business and will position the company as one of the top three global suppliers of Ibuprofen.  

Logo - http://photos.prnewswire.com/prnh/20130204/NY53537LOGO-b

"It's the largest deal in SI Group's history," said Frank Bozich, SI Group President & CEO. "This acquisition is a natural fit to our expansion strategy, transforming SI Group into a solutions leader in the global antioxidant and pharmaceutical active ingredients markets." 

The acquisition will include Albemarle's antioxidant product lines, as well as the FDA-regulated Ibuprofen and Propofol businesses. In addition, applications and technical support capabilities in Shanghai and Baton Rouge, Louisiana, United States will be included in the transaction.

"This acquisition is a major step in SI Group's strategy of expanding into complementary, faster growing markets while at the same time continuously improving our core business through business excellence," said Stephen Haller, Senior Vice President of Strategy and New Business Development.

Subject to the required regulatory approvals, this acquisition is expected to be completed later this year. Additional information about SI Group may be found at www.siigroup.com.

About SI Group

SI Group is a leading global developer and manufacturer of chemical intermediates, specialty resins, and solutions. Founded in 1906 and headquartered in Schenectady, New York, SI Group is a family-owned company with facilities in 10 countries. For more information about SI Group, visit www.siigroup.com.

Contact:
Brooke Manrique
Public Relations & Marketing Communications Manager
SI Group, Inc.
+1-518-347-4112
[email protected]

Modal title

Also from this source

SI GROUP BUILDS EMEA DISTRIBUTION NETWORK THROUGH NEW PARTNERSHIP WITH AZELIS

SI GROUP BUILDS EMEA DISTRIBUTION NETWORK THROUGH NEW PARTNERSHIP WITH AZELIS

SI Group, a leading global developer and manufacturer of performance additives, process solutions, pharmaceuticals, and chemical intermediates,...

SI GROUP TO SHOWCASE SUSTAINABLE ADDITIVE INNOVATIONS AT K 2025

SI GROUP TO SHOWCASE SUSTAINABLE ADDITIVE INNOVATIONS AT K 2025

SI Group, a leading global developer and manufacturer of performance additives, process solutions, pharmaceuticals, and chemical intermediates, will...

More Releases From This Source

Explore

Medical Pharmaceuticals

Medical Pharmaceuticals

Chemical

Chemical

Chemical

Chemical

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +91 22-69790010

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+91 (0) 22 6169 6000
from 9 AM - 5:30 PM IST
  • Terms of Use
  • Privacy Policy
  • GDPR
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.